Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 5.3% – What’s Next?

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) were down 5.3% during trading on Tuesday . The stock traded as low as $26.91 and last traded at $27.32. Approximately 118,307 shares changed hands during trading, a decline of 67% from the average daily volume of 357,884 shares. The stock had previously closed at $28.84.

Analyst Ratings Changes

Several analysts have commented on AVLN shares. Morgan Stanley started coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target for the company. Evercore assumed coverage on shares of Avalyn Pharma in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price objective for the company. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $52.00 target price on the stock. Finally, Guggenheim initiated coverage on shares of Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $80.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to data from MarketBeat, Avalyn Pharma currently has an average rating of “Strong Buy” and an average price target of $59.00.

Avalyn Pharma Trading Up 5.9%

Insider Activity at Avalyn Pharma

In other news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jill Carroll bought 277,778 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 14.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.